Tharimmune receives positive regulatory feedback from ema for th104 clinical program for chronic pruritus in primary biliary cholangitis

Bridgewater, nj / accesswire / october 30, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a scientific advice meeting with the european medicines agency (ema) that included guidance on a planned phase 2 trial to advance th104, the company's lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary cholangitis (pbc). the ema interactions specifically focused on both the phase 2 and phase 3 clinical program of th104.
THAR Ratings Summary
THAR Quant Ranking